CeQur is looking to treble the size of its workforce in Massachusetts with an expansion of the plant in Marlborough it plans to use to make the PaQ insulin device it hopes to launch this year. PaQ, a patch-like device, is designed to deliver both basal insulin and on-demand bolus insulin over 3 days. CeQur says it’s optimized the […]
CeQur SA
Diabetes: CeQur raises $100m for PaQ 3-day insulin device
CeQur said today that it raised a Series C round worth $100 million in what its backers called the largest medtech financing in Europe since 2006. CeQur said it plans to use the proceeds to further the planned 2016 launch of the 2nd generation of its PaQ 3-day insulin device for Type II diabetics. Woodford Investment Management and Arthurian Life […]
CeQur names medtech veteran as new CEO | Medtech personnel moves for the week of Apr. 14, 2014
CeQur gets new CEO from Becton Dickinson | Personnel Moves
April 11, 2014 by Arezu Sarvestani
Switzerland-based insulin delivery devices maker CeQur named medtech veteran Douglas Lawrence its new CEO, replacing James Peterson.
CeQur gets new CEO from Becton Dickinson | Personnel Moves
Switzerland-based insulin delivery devices maker CeQur named medtech veteran Douglas Lawrence its new CEO, replacing James Peterson.
Lawrence has spent more than 25 years in the medical device industry, most recently as vice president of the insulin injection business at Becton, Dickinson’s (NYSE:BDX) diabetes arm.
Diabetes: CeQur CEO Jim Peterson’s personal mission to improve the standard of care
Most people are brought into the medical device industry because of a passion for a specific disease or a personal connection to a condition that’s had an impact on his or her life.
For Jim Peterson, the CEO and founder of CeQur, that motivation was right inside his own house. His daughter was diagnosed with Type I diabetes at 3 years old.
Diabetes: CeQur closes $27B Series B round
CeQur SA is planning to scale up manufacturing of its PaQ insulin delivery device in Europe with a $27 million Series B round.
The Horw, Switzerland-based company said the round was led by a pair of new, private investors and was joined by all existing backers, including BMC Ventures A/S, Endeavour Vision SA, Schroder & Co. Bank AG and Venture Incubator AG.
CeQur lands CE Mark for its PaQ continuous insulin delivery device
CeQur SA received CE Mark approval to commercialize its PaQ insulin delivery devices in the European market, the company reported this week.
The PaQ insulin delivery system features a disposable insulin-infuser reservoir attached to a reusable insulin monitor and provides 3 days of continuous basal insulin delivery and on-demand bolus insulin for individuals with Type II diabetes, the company said.
